<DOC>
	<DOCNO>NCT00515437</DOCNO>
	<brief_summary>To determine safety , tolerability preliminary efficacy intraglandular injection MYOBLOC treatment sialorrhea Parkinsons ' Disease patient</brief_summary>
	<brief_title>A Multi-Center Study MYOBLOC Treatment Sialorrhea Parkinson 's Disease Patients</brief_title>
	<detailed_description>This multi-center , outpatient , double-blind , placebo-controlled , single treatment , sequential dose escalation study design evaluate safety , tolerability preliminary efficacy single dos MYOBLOC versus placebo treatment sialorrhea Parkinson 's disease patient , last approximately 20 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>Parkinsons ' Disease patient Sialorrhea least 3 month Patients nonidiopathic PD parkinsonism Patients previously expose botulinum toxin Patients history aspiration pneumonia , moderate/severe choke and/or moderate/severe dysphagia Patients prior salivary gland surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Sialorrhea</keyword>
</DOC>